Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.
Diguet
E
E
Gross
C E
CE
Bezard
E
E
Tison
F
F
Stefanova
N
N
Wenning
G K
GK
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism; D002986:Clinical Trials as Topic; D003342:Corpus Striatum / Q000187:drug effects; D004195:Disease Models, Animal; D017628:Microglia / Q000187:drug effects / Q000378:metabolism; D008911:Minocycline / Q000009:adverse effects / Q000627:therapeutic use*; D009043:Motor Activity / Q000187:drug effects; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016627:Oxidopamine; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy*; D011323:Primates; D017378:Quinolinic Acid; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000187:drug effects; D017211:Treatment Failure
D018696:Neuroprotective Agents; D016627:Oxidopamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D017378:Quinolinic Acid; D008911:Minocycline